RecruitingPhase 3NCT07328854
40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ming-Yuan Chen
- Principal Investigator
- Ming-Yuan Chen, MD,PhDSun Yat-sen University
- Intervention
- Cisplatin-based induction chemotherapy(drug)
- Enrollment
- 346 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2032
Study locations (15)
- Anhui Provincial Cancer Hospital, Hefei, Anhui, China
- Fujian Cancer Hospital, Fuzhou, Fujian, China
- Sun Yat-sen University cancer center, Guangzhou, Guangdong, China
- the Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China
- Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China
- Zhongshan City People's Hospital, Zhongshan, Guangdong, China
- The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China
- Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China
- Wuzhou Red Cross Hospital, Wuzhou, Guangxi, China
- Central South University Cancer Hospital,, Changsha, Hunan, China
- Xiangya Hospital of Central South University, Changsha, Hunan, China
- West China Hospital, Sichuan University, Chengdu, Sichuan, China
- The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, China
- Yunnan Cancer Hospital, Kunming, Yunnan, China
- Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07328854 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu
- RECRUITINGNCT07232680Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon ChemoradiotherapyCheng-En Hsieh
- RECRUITINGPHASE3NCT07328841Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and ImmunotherapyMing-Yuan Chen